Thyrotropin-Releasing Hormone clinical trials
How each study uses Thyrotropin-Releasing Hormone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 5 Nov 1976 · THYPINONE · NDA 017638 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 1993 (1)
| Year | Studies |
|---|---|
| 1993 | 1 |
| 1998 | 1 |
| 2003 | 1 |
| 2006 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 5
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · National Center for Research Resources (NCRR) (1) · UConn Health (1) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses Thyrotropin-Releasing Hormone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid CancerWithdrawnPhase 1Memorial Sloan Kettering Cancer CenterNCT04868045Written as Thyrotropin Releasing Hormone (TRH)
- Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary AbnormalitiesCompletedPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT00054756Written as TRH (Thyrotropin Releasing Hormone)
- Evaluation of Synthetic Thyrotropin Releasing Hormone (TRH) as a Treatment for Cancer-related FatigueTerminatedPhase 2UConn HealthNCT00790296Written as Thyrotropin releasing hormone (TRH)
- Study of Antenatal Thyrotropin-Releasing Hormone in Women in Premature Labor to Prevent Lung Disease in Preterm InfantsCompletedNot applicableEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NCT00004840Written as thyrotropin-releasing hormone
- Phase III Randomized, Double-Blind, Placebo-Controlled Study of Antenatal Thyrotropin-Releasing Hormone in Pregnant Women With Threatened Premature DeliveryCompletedPhase 3National Center for Research Resources (NCRR)NCT00004778Written as thyrotropin-releasing hormone
Given beside what is tested · 1 — Thyrotropin-Releasing Hormone is usual care or a partner of the new treatment
Codes
What other systems call Thyrotropin-Releasing Hormone · ClinicalTrials.gg INT008324
- MeSH (NLM) D013973Thyrotropin-Releasing HormoneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 1N3H4TJE79PROTIRELIN TARTRATE MONOHYDRATEConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D013973 | Thyrotropin-Releasing Hormone | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 1N3H4TJE79 | PROTIRELIN TARTRATE MONOHYDRATE | Confirmed FDA, NLM |
Also registered as protirelin (UNII 5Y5F15120W · RxNorm 10580) and protirelin tartrate (UNII SYW8T997EQ).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.